CTMX Nov 2024 4.000 put
| Previous close | 2.5000 |
| Open | 2.5000 |
| Bid | 1.0500 |
| Ask | 3.1000 |
| Strike | 4.00 |
| Expiry date | 2024-11-15 |
| Day's range | 2.5000 - 2.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
GlobeNewswireCytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 2:00 p.m. ET. A live webcast of the presentation will be available on the Events and Presenta
- GlobeNewswire
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has made broad contributions as a member of the CytomX executive team and is a proven cross-functional leader within the organization,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. “We are ex
Simply Wall St.Shareholders in CytomX Therapeutics (NASDAQ:CTMX) are in the red if they invested five years ago
We're definitely into long term investing, but some companies are simply bad investments over any time frame. We really...
